Zivo Bioscience, Inc. (ZIVOW) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-24

Key Insights

Director Mark E. Strome and affiliated entities (Strome Mezzanine Fund II, LP and related investment vehicles) acquired 100,000 common shares at $2.00 per share on 04/17/2026, representing a $200,000 investment in the company.
The transaction was conducted through Strome Mezzanine Fund II, LP pursuant to a Securities Purchase Agreement, indicating an institutional investment rather than open market purchase, suggesting confidence in the company's direction.
Following this transaction, the reporting persons beneficially own 572,942 shares indirectly through the fund structure, establishing a significant equity position that subjects them to Section 16 reporting obligations as a director and 10% owner.
The filing includes explicit disclaimers that it does not constitute an admission of beneficial ownership under Section 16, suggesting the reporting persons may be contesting full insider classification despite the substantial shareholding.

Want the newest filings?

This analysis covers the filing from 2026-04-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-27

Laith L. Yaldoo, a director and 10% owner of Zivo Bioscience, Inc. (ZIVO), purchased 1,766 shares of common stock on January 14, 2026 at a price of $8.49 per share.
This insider buying activity suggests Yaldoo has a positive outlook on the company's prospects and is willing to increase his stake.
The size of the transaction, while not exceptionally large, is still notable and may signal confidence in the company's future performance.

Filed: 2026-01-27

The reporting person, Christopher D. Maggiore, acquired 1,766 shares of Zivo Bioscience, Inc. (ZIVOW) common stock at $8.49 per share on January 14, 2026, increasing his direct beneficial ownership to 519,292 shares.
Maggiore is both a director and a 10% owner of Zivo Bioscience, indicating his significant stake and involvement in the company.
The insider purchase suggests Maggiore's confidence in Zivo Bioscience's prospects and potential future performance.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.